PEPA – Kodiac biolabs

Plain-language summaryIntrigue 32 / 100

PEPA is a sulfonamide AMPA potentiator developed in Japan. Used as a research probe for AMPA receptor pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

42/100

Potent AMPA PAM with sharp in vitro probe value but fatal PK and no translational signal

Look, PEPA occupies a very specific niche in the AMPA receptor pharmacology toolkit, and understanding that niche is the whole story. The compound’s core value is as a high-potency positive allosteric modulator of AMPA-type glutamate receptors, and its sulfonamide scaffold gives it a mechanistic fingerprint distinct from the benzamide ampakines like CX-614 or the aniracetam derivatives that most investigators reach for first. AMPA receptor potentiation is genuinely interesting biology. Positive allosteric modulation slows receptor desensitization and deactivation, amplifies AMPA-mediated currents, and downstream recruits BDNF signaling cascades implicated in LTP and synaptic consolidation. That’s a real mechanism with real relevance to cognitive neuroscience.

Here’s the thing though: PEPA’s potency advantage over marketed ampakines is real in vitro and essentially academic in vivo. The compound has poor oral bioavailability and a short plasma half-life that have kept it firmly in the cell culture and slice prep world. Investigators trying to use it for in vivo behavioral work face serious delivery challenges that newer AMPA PAMs in the research literature dont have. That PK profile isn’t a minor inconvenience, it’s a structural limitation that caps how much you can ask of this compound as a research tool.

What we like: the potency-per-molecule is legitimately high, and for receptor binding studies, selectivity profiling, and electrophysiology in brain slices, PEPA gives you sharp, clean AMPA potentiation that’s useful for dissecting receptor subtype contributions. The sulfonamide scaffold also offers SAR diversity that benzamide-class AMPA PAMs dont, which gives it genuine value for chemists doing scaffold comparisons or exploring allosteric site geometry. For a program centered squarely on AMPA receptor biology, this compound earns a spot on the shelf.

What we dont like: availability is a real constraint. PEPA hasn’t crossed into research-chemical-grade commercial supply in any meaningful way, which means sourcing is limited to academic supply chains and adds friction to any program trying to use it at scale. And without human data of any kind, its translational story is essentially zero. The broader ampakine class has had a rough decade in Phase 2 trials, and PEPA’s poor PK means it was never even a candidate to generate the kind of clinical signal that would make it more interesting from an investment standpoint.

Honestly, this is a probe compound doing exactly what probe compounds are supposed to do: give you mechanistic resolution in controlled in vitro settings. For AMPA receptor pharmacologists specifically, its genuinely useful. For anyone outside that niche, theres little reason to engage with it over compounds that offer better translational geometry. A score of 42 reflects that accurately. High bench value in a narrow context, with almost nothing pointing toward broader relevance.

Novelty: 38
Mechanism promise: 58
In-category differentiation: 42
Evidence quality: 38
Translational signal: 18
Research bench value: 60

Rationale PEPA’s primary scoring axis is bench value as a high-potency sulfonamide AMPA PAM with a distinct mechanistic fingerprint from the benzamide ampakines, but poor oral bioavailability and a short plasma half-life confine it to cell culture and slice prep applications, producing essentially zero translational signal and dragging the overall down to niche-probe territory; novelty is modest because AMPA PAMs as a class date to the 1990s.

Sulfonamide AMPA potentiator

A potent benzothiazide AMPA potentiator used principally as a research probe for AMPA receptor pharmacology.

Abstract

PEPA (4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluoro-phenoxyacetamide; CAS 158235-23-7) is a potent sulfonamide-class AMPA receptor positive allosteric modulator developed as a research tool compound. The compound shows substantially greater AMPA potentiation per molecule than the marketed and Phase 2 ampakines, but with poor pharmacokinetic properties (low oral bioavailability, short plasma half-life) that limit clinical translation. PEPA is used principally as a research probe for AMPA receptor pharmacology in vitro and ex vivo. The compound has not been advanced to human clinical trials and has no significant research-chemical-grade availability outside academic research supply chains.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-059Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.